🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.400
-0.160 (-10.26%)
At close: Nov 19, 2026, 4:00 PM EST
1.427
+0.027 (1.93%)
After-hours: Nov 19, 2026, 7:30 PM EST

Acrivon Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.924.1225.2121.088.712.47
Research & Development
58.359.9963.9946.0223.9513.72
Operating Expenses
77.284.1189.267.132.6616.18
Operating Income
-77.2-84.11-89.2-67.1-32.66-16.18
Interest & Investment Income
3.846.489.27.04--
Currency Exchange Gain (Loss)
0.20.2-0.1---
Other Non Operating Income (Expenses)
-1.17-0.91-4.24-3.650.79-0.06
EBT Excluding Unusual Items
-74.33-78.34-84.33-63.71-31.87-16.24
Gain (Loss) on Sale of Investments
0.440.443.783.320.7-
Pretax Income
-73.89-77.91-80.56-60.39-31.17-16.24
Net Income
-73.89-77.91-80.56-60.39-31.17-16.24
Net Income to Common
-73.89-77.91-80.56-60.39-31.17-16.24
Net Income Growth
------
Shares Outstanding (Basic)
4139342242
Shares Outstanding (Diluted)
4139342242
Shares Change
5.53%13.96%53.05%435.63%136.43%21.70%
EPS (Basic)
-1.82-2.02-2.38-2.74-7.56-9.32
EPS (Diluted)
-1.82-2.02-2.38-2.74-7.56-9.32
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-63.34-65.33-68.44-43.93-32.28-14.22
Free Cash Flow Per Share
-1.56-1.70-2.02-1.99-7.83-8.16
EBITDA
-75.64-82.76-88.19-66.57-32.29-16.15
D&A For EBITDA
1.561.361.010.540.360.04
EBIT
-77.2-84.11-89.2-67.1-32.66-16.18
SEC Filings: 10-K · 10-Q